Head-to-head evidence
Datopotamab Deruxtecan vs LCB84
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline
Datopotamab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT04484142 · Phase 2 · completed
This was an open-label, single-arm study without randomization or a comparator, although tumor responses were assessed by blinded independent central review. The primary clinical endpoint was objective response rate, reported as 35.8%, but without a control arm there was no formal comparative endpoint test.
Next expected readout: May 2027 · NCT04644068 (registry estimate)
LCB84
Developed by LigaChem Biosciences, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Datopotamab Deruxtecan's landscape · LCB84's landscape